Diabetes monitoring strong for Roche, Bio-Rad, but not for Becton Dickinson
This article was originally published in Clinica
Factors behind Becton Dickinson's strong growth in its third quarter ended June 30 2003 included a 19% increase to $648m in its medical system revenues. Sales of newer safety products grew, but to some extent were offset by lower revenues from conventional devices. The company said its ProbeTec molecular diagnostic platform performed well worldwide, but sales in blood glucose monitoring - a relatively new area for the group - disappointed analysts.